-+ 0.00%
-+ 0.00%
-+ 0.00%

Praxis Precision Medicines Q3 2026 net loss widens 27% to $94.2 million

PUBT·11/09/2026 12:06:56
Listen to the news
Praxis Precision Medicines Q3 2026 net loss widens 27% to $94.2 million
  • Praxis Precision Medicines’ third-quarter 2026 net loss widened 27% year over year to $94.2 million.
  • General and administrative expenses more than tripled year over year to $42.7 million.
  • Cash, cash equivalents and marketable securities totaled $1.3 billion at September 30, 2026, providing an expected runway into 2028.
  • FDA target action dates remain December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide.
  • Topline results from relutrigine’s EMERALD study in broad developmental and epileptic encephalopathies are expected in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9872955) on November 09, 2026, and is solely responsible for the information contained therein.